{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid6b37itv6sruguusdtip5bxt4ipnesgbivmu44blkzfl5frrwoqy",
    "uri": "at://did:plc:izotgtw5czjnuqtpcldjnkjh/app.bsky.feed.post/3mkmuby6k47g2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreic5z2rcdagvpzopv3rkvfmol4vn4uoz7kgo7w3ikpomarugtl4xva"
    },
    "mimeType": "image/jpeg",
    "size": 205574
  },
  "path": "/breakthrough-bowel-cancer-trial-leaves-patients-cancer-free-for-nearly-3-years/",
  "publishedAt": "2026-04-29T05:34:47.000Z",
  "site": "https://scitechdaily.com",
  "tags": [
    "Health",
    "Cancer",
    "Gastroenterology",
    "Immunotherapy",
    "University College London"
  ],
  "textContent": "A new approach to treating certain bowel cancers is showing long-lasting effects. Patients with a particular form of bowel cancer have remained cancer-free for nearly three years after receiving a short course of immunotherapy before surgery, rather than chemotherapy afterward. These findings come from the NEOPRISM-CRC clinical trial led by researchers at UCL and UCLH. [...]",
  "title": "Breakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years"
}